Biofrontera
Yahoo Finance • 2 years ago
Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Ben... Full story
Yahoo Finance • 2 years ago
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, toda... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
Sets company up to realize full commercial potential in fast growing U.S. marketSupports mutually beneficial interests between Biofrontera Inc and Biofrontera AG WOBURN, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
Four Posters Highlighting Results from Investigator-Initiated and Company-Sponsored Research with Ameluz to be Presented WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company speci... Full story
Yahoo Finance • 2 years ago
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc.’s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology
WOBURN, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decis... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializin... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it has entered into agreements with certain o... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022
WOBURN, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary unaudited product revenues for th... Full story
Yahoo Finance • 2 years ago
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The... Full story
Yahoo Finance • 3 years ago
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the Ameri... Full story
Yahoo Finance • 3 years ago
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 m... Full story
Yahoo Finance • 3 years ago
Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:0a.m. Eastern time today WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological p... Full story
Yahoo Finance • 3 years ago
Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022
WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March... Full story
Yahoo Finance • 3 years ago
Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®
Ameluz® for the treatment of actinic keratoses now at www.ameluz.com Xepi® for the treatment of impetigo now at www.xepicream.com WOBURN, Mass. , April 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical c... Full story
Yahoo Finance • 3 years ago
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
Significantly Improves Manufacturing Efficiency,Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization... Full story
Yahoo Finance • 3 years ago
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
Introduces 2022 financial guidance Conference call begins at 11:0a.m. Eastern time today WOBURN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the... Full story
Yahoo Finance • 3 years ago
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the thr... Full story
